188 related articles for article (PubMed ID: 17420189)
1. FDA's sentinel network: a monumental task.
Young D
Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
[No Abstract] [Full Text] [Related]
2. Report slams US FDA's drug safety reform efforts.
Bristol N
Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
[No Abstract] [Full Text] [Related]
3. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.
Sarangdhar M; Tabar S; Schmidt C; Kushwaha A; Shah K; Dahlquist JE; Jegga AG; Aronow BJ
Nat Biotechnol; 2016 Jul; 34(7):697-700. PubMed ID: 27404875
[No Abstract] [Full Text] [Related]
4. Human factors and medical IT systems: complex incident reporting systems and multiple IV infusions.
Colvin C; Baird P; Easty T; Trbovich P
Biomed Instrum Technol; 2013; Suppl():59-63. PubMed ID: 24111773
[No Abstract] [Full Text] [Related]
5. Documenting an adverse drug reaction.
Smith LS
Nursing; 2005 Oct; 35(10):22. PubMed ID: 16205246
[No Abstract] [Full Text] [Related]
6. FDA's adverse-event surveillance needs improvement, advisers say.
Traynor K
Am J Health Syst Pharm; 2005 Jul; 62(13):1336, 1338, 1340. PubMed ID: 15972368
[No Abstract] [Full Text] [Related]
7. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
Psaty BM; Burke SP
N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
[No Abstract] [Full Text] [Related]
8. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
[TBL] [Abstract][Full Text] [Related]
9. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
Hauben M; Reich L; DeMicco J; Kim K
Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
[No Abstract] [Full Text] [Related]
10. Pharmacovigilance: methods, recent developments and future perspectives.
Härmark L; van Grootheest AC
Eur J Clin Pharmacol; 2008 Aug; 64(8):743-52. PubMed ID: 18523760
[TBL] [Abstract][Full Text] [Related]
11. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
Kuehn BM
JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
[No Abstract] [Full Text] [Related]
12. Estimating the rate of adverse drug reactions with capture-recapture analysis.
Seeger JD; Schumock GT; Kong SX
Am J Health Syst Pharm; 1996 Jan; 53(2):178-81. PubMed ID: 8653485
[TBL] [Abstract][Full Text] [Related]
13. Anatomy of Risk Evaluation and Mitigation Strategies (REMS).
Loeser KK; McKoy JM; Schumock GT
Cancer Treat Res; 2019; 171():93-105. PubMed ID: 30552659
[TBL] [Abstract][Full Text] [Related]
14. Data incompatibility of adverse event reports electronically submitted to the AERS database.
Glass LM
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):212-3. PubMed ID: 18236510
[No Abstract] [Full Text] [Related]
15. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Litigation-Associated Reports on Signal Identification in the US FDA's Adverse Event Reporting System.
Muñoz MA; Dal Pan GJ
Drug Saf; 2019 Oct; 42(10):1199-1201. PubMed ID: 31098918
[No Abstract] [Full Text] [Related]
17. Sidelining safety--the FDA's inadequate response to the IOM.
Smith SW
N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
[No Abstract] [Full Text] [Related]
18. Improving detection of adverse effects of marketed drugs.
Klein DF; O'Brien CP
JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
[No Abstract] [Full Text] [Related]
19. Shared REMS programs expanded in 2012.
Traynor K
Am J Health Syst Pharm; 2013 Feb; 70(4):298, 303. PubMed ID: 23370134
[No Abstract] [Full Text] [Related]
20. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
